The purpose of the study is to explore whether this treatment switch can improve the PSA response in this setting. In the study, participants first receive the standard hormone-based treatment, and then treatment is changed to BMS-986365. The study then follows how the cancer and symptoms change over time, while also checking for side effects, blood test changes, and heart tracing changes. The study also looks at general health and pain over the course of treatment.

After the first treatment with apalutamide and hormone therapy, the study compares continued treatment with apalutamide plus docetaxel and hormone therapy. Treatment is given over time, with regular study visits and follow-up checks. During the study, doctors watch for changes in the cancer, possible side effects, and how long the treatment continues to work. The study is Phase III, which means it is a late-stage trial designed to better understand how well this treatment approach works and how safe it is.

One of the treatments being tested is lutetium (177lu) vipivotide tetraxetan, which is administered as a solution for injection or infusion directly into a vein. This medication is a type of radiopharmaceutical, meaning it contains a small amount of radiation designed to target cancer cells. The study follows a specific design to compare different treatment approaches against standard care to see which options are most effective for patients.

During the study, participants will take their assigned medications by mouth as tablets or capsules. They will continue their ongoing hormone therapy that lowers testosterone levels throughout the study. The study will track how long it takes for the cancer to get worse by using imaging scans, which are special pictures of the inside of the body taken with machines. The study team will also monitor various aspects of health, including blood tests to measure a substance called prostate-specific antigen, pain levels, quality of life, and any side effects that may occur. Participants will attend regular visits where doctors will perform examinations and tests to assess how the treatment is working and how participants are feeling.

The study will also look at other important measures such as how long participants live, whether tumors shrink in response to treatment, how long any tumor shrinkage lasts, and how long it takes before additional cancer treatments are needed. Doctors will carefully monitor for any unwanted effects of the medications and will check participants’ overall well-being through questionnaires about pain, tiredness, and daily functioning. Blood samples will be taken at certain times to measure the levels of mevrometostat in the body and to examine genetic material from cancer cells that may be circulating in the blood.

During the study, patients will undergo PSMA PET/CT scans, which are special imaging tests that combine two types of scans to find and measure prostate cancer in the body. These scans will be done before starting the treatment and again after taking darolutamide to compare the results. The study will look at whether the number of cancer deposits increases, whether existing cancer spots show higher levels of the PSMA protein, or whether the cancer spots become larger or more visible after treatment with darolutamide. This effect, where the visibility of cancer temporarily increases after starting certain hormone-blocking treatments, is sometimes called a flare phenomenon.

Patients participating in this study will have already received previous treatment for their prostate cancer, either surgery to remove the prostate or radiation therapy, and their scans will show between one and five areas where the cancer has spread to bones or lymph nodes. The study will also collect information about any side effects that occur and how patients feel during the treatment by using quality of life questionnaires. The measurements taken during the scans will include the number of cancer spots, their size, their location in the body, and a measurement called SUVmax which indicates how much the PSMA protein is present in each spot.

The study has two parts with different purposes. The first part will determine the appropriate doses of tulmimetostat when given together with darolutamide and when given together with abiraterone. This part will also look at how safe these combinations are and how well people tolerate them. The second part will compare how well tulmimetostat combined with darolutamide works compared to darolutamide given alone. The main goal is to see how many men achieve very low levels of a substance in the blood called PSA, which is a marker used to monitor prostate cancer. This will be measured at six months and confirmed by a second measurement at least three weeks later.

During the study, participants will take the study medications as tablets by mouth. The study will monitor various aspects of how the treatment affects the cancer and the participant’s health. This includes measuring changes in PSA levels, checking how long it takes for the cancer to grow or spread using imaging scans, measuring overall survival, and evaluating tumor size changes. The study will also carefully track any side effects and how well participants tolerate the medications by looking at things like dose changes, treatment interruptions, and any problems with blood tests, vital signs, or heart function tests. Blood samples will be collected to measure the levels of the study medications in the body.

The study compares different doses of luxdegalutamide (100 mg or 300 mg daily) combined with abiraterone against standard hormone therapy. Participants will also receive medications to lower testosterone levels, either through degarelix injections or other similar drugs. The treatment continues for several months to determine which dose combination works best while monitoring safety and effectiveness.

Throughout the study, doctors will track how well the treatment works by measuring PSA (prostate-specific antigen) levels in the blood and using imaging tests to check if the cancer is shrinking. They will also monitor any side effects and how well patients tolerate the treatment. The study aims to find the most effective and safest dose combination to help treat this type of prostate cancer.

The purpose of the study is to compare two approaches to hormone therapy: intermittent maximum androgen blockade (iMAB) and continuous maximum androgen blockade (cMAB). The study aims to determine the benefits and risks of these approaches in patients who have shown a significant response to initial hormone therapy. Participants will be randomly assigned to either continue their hormone therapy without interruption or to have breaks in their treatment. The study will monitor how long patients can go without restarting hormone therapy and compare the overall survival rates between the two groups.

Throughout the study, participants will be observed for changes in their quality of life, including physical functioning, sexual activity, and pain levels. The study will also track the time it takes for patients to need additional prostate cancer treatments and monitor their testosterone and PSA (prostate-specific antigen) levels. The trial will help determine if taking breaks in hormone therapy can maintain the same level of cancer control as continuous treatment while potentially improving the quality of life for patients.

Participants in the study will receive either the new treatment, Lutetium-177-PSMA, or follow the standard care. The treatment involves an injection of a solution that contains a radioactive substance, which is designed to target and destroy cancer cells. The study will monitor the participants to see how their cancer responds to the treatment and whether it helps in delaying the progression of the disease. The study will also look at other factors such as the participants’ quality of life and any side effects they may experience.

The trial will last for several months, and participants will be closely monitored throughout the process. The researchers aim to gather valuable information that could lead to improved treatment options for patients with prostate cancer. This study is an important step in exploring new ways to manage and treat this type of cancer, potentially offering new hope for patients in the future.

Participants in the study will receive either the combination treatment or the standard care alone. The study will monitor the progress of the disease using imaging techniques to see if the cancer is spreading or staying the same. The trial will also look at overall survival, which means how long patients live after starting the treatment, and other health outcomes. The study will last for a period of time, and participants will be regularly checked to see how they are responding to the treatment.

This trial is important for understanding if adding 177Lu-PSMA-617 to the standard care can improve outcomes for patients with mHSPC. The study will help determine if this new combination treatment can help control the cancer more effectively than the standard care alone. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

The purpose of the study is to see if adding 177Lu-PSMA-617 can help control the disease better than the standard treatments alone. The standard treatments may include medications such as enzalutamide, apalutamide, darolutamide, and abiraterone acetate, which are taken orally, as well as Pluvicto, which is given as an injection or infusion. The study will involve regular monitoring of the patients’ health and response to the treatment over a period of time. This will help researchers understand the effectiveness and safety of the new treatment approach.

Participants in the study will receive either the standard treatment alone or the standard treatment plus 177Lu-PSMA-617. The study will track how long patients live and how long they remain free from cancer progression. It will also look at other factors such as quality of life and any side effects experienced. The goal is to determine if the new treatment can improve outcomes for patients with this type of prostate cancer.

The purpose of this study is to determine if darolutamide can lower prostate-specific antigen (PSA) levels as effectively as standard hormone therapy after 24 weeks of treatment. The study will also look at how these treatments affect symptoms related to prostate cancer and monitor the safety of both treatment approaches.

During the study, patients will be randomly assigned to receive either darolutamide tablets or one of the standard hormone therapy medications. The treatment period lasts for 24 weeks, during which patients will have regular check-ups to measure PSA levels and assess their response to treatment. The study will also track any side effects and changes in quality of life that patients may experience during treatment.

The purpose of this study is to compare how well the combination of Capivasertib and Abiraterone works against the combination of a placebo and Abiraterone in patients with this specific type of prostate cancer. The study will monitor how long patients live without their cancer getting worse, which is known as radiographic progression-free survival. Participants will be randomly assigned to receive either the Capivasertib and Abiraterone combination or the placebo and Abiraterone combination. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed.

Throughout the study, participants will take the medication orally and will have regular check-ups to monitor their health and the progression of their cancer. The study aims to provide valuable information on the potential benefits of adding Capivasertib to the treatment regimen for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial is expected to continue until 2027, with recruitment starting in 2024.

The trial involves several medications, including abiraterone, capivasertib, enzalutamide (also known as MDV3100), niraparib, darolutamide (also known as ODM-201 or BAY 1841788), cabazitaxel, olaparib, docetaxel, and radium ra 223 dichloride. These medications are used in different combinations to see how well they work in slowing down the progression of the cancer. Some of these drugs are taken orally as tablets, while others are given through intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

Participants in the study will receive one of these treatments or a placebo, and their progress will be monitored over time to see how the cancer responds. The study will help researchers understand which treatments are most effective for patients with specific genetic markers, potentially leading to more personalized and effective treatment options for those with metastatic prostate cancer.

The trial involves adult male patients who have prostate cancer that shows positive results for a specific marker called prostate-specific membrane antigen (PSMA). The study uses a special type of imaging called Positron Emission Tomography (PET) to identify the presence of PSMA in the cancer. Patients will receive either the treatment or be placed under observation, and their progress will be monitored over time to see how the treatment affects the spread of cancer.

Participants in the study will undergo regular imaging tests, such as CT or MRI scans, to track the presence of cancer in the body. The main goal is to determine how long patients can remain free from new cancer growth or the need for additional treatment. The study will also look at other factors, such as the time it takes for the cancer to progress and the overall health and quality of life of the participants. The trial is expected to continue until 2030, with recruitment starting in 2024.

The purpose of this research is to determine if adding abemaciclib to a combination of abiraterone and prednisone helps slow down the progression of cancer that can be seen on imaging scans. The study focuses particularly on high-risk cases where cancer has spread significantly to the bones or to internal organs such as the lungs or liver.

During the study, participants will take their assigned medications orally (by mouth) each day. The treatment period will last 28 days per cycle, and participants will be monitored regularly to check how their cancer responds to treatment and to watch for any side effects. Various aspects of the participants’ health will be evaluated throughout the study, including their pain levels and overall quality of life.

The purpose of the study is to determine if adding short-term hormone therapy or androgen receptor targeted therapy (ARTA) to MDT can significantly extend the time patients remain free from more severe forms of prostate cancer. The study will involve regular monitoring of patients to track the progression of the disease and assess the effectiveness of the treatments. Participants will receive these treatments through injections or oral capsules over a period of several months, depending on the specific medication and treatment plan.

Throughout the study, patients will undergo various assessments, including imaging tests like PSMA PET-CT or PSMA PET-MRI, to evaluate the presence and progression of cancer. The study will also monitor the quality of life and any side effects experienced by participants. The ultimate goal is to find the most effective treatment strategy for managing oligorecurrent prostate cancer and improving patient outcomes.

The purpose of the study is to compare the safety of these treatment regimens by looking at the occurrence of serious side effects. The study will also monitor for a specific side effect called neutropenia, which is a low level of white blood cells that can increase the risk of infection. Patients will undergo six cycles of treatment, and the study will track their health and any side effects they experience during this time. The trial will also assess other outcomes, such as overall survival, the time it takes for the cancer to become resistant to hormone therapy, and the quality of life of the participants.

Participants in the study will receive their treatments either as an intravenous infusion, which is a method of delivering medication directly into the bloodstream, or as oral tablets. The study aims to provide valuable information on the best way to use docetaxel in combination with darolutamide and ADT for treating this type of prostate cancer. The results could help improve treatment strategies and outcomes for patients with this condition.